{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-075034","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.160128+00:00","generated_at":"2026-05-17T14:27:44.133392+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Citius Pharma Q3 fiscal 2025 net loss narrows to $9.2M; LYMPHIR launch on track for Q4","bullets":["Net loss of $9.2M ($0.80 per share) vs $10.6M ($1.57 per share) in the prior-year quarter.","Cash and equivalents $6.1M at June 30; raised $12.5M in gross financings during the quarter.","LYMPHIR launch for cutaneous T-cell lymphoma planned Q4 2025; manufacturing and distribution agreements in place.","Citius Oncology raised additional $9M in July 2025 to fund pre-launch activities.","Mino-Lok discussions with FDA continue; evaluating best path forward for antibiotic lock solution."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-075034","json":"https://secwatch.observer/filing/0001213900-25-075034.json","markdown":"https://secwatch.observer/filing/0001213900-25-075034.md","text":"https://secwatch.observer/filing/0001213900-25-075034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025075034/0001213900-25-075034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025075034/ea0252899-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:27:44.133392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}